ArticleUS ophthalmic review2017
Advances in Age-related Macular Degeneration Understanding and Therapy.
Article in US ophthalmic review, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Clinical effectiveness of screening for age-related macular degeneration: A systematic review.PloS one · 2023Pooled it
- Diosgenin mitigates laser-induced choroidal neovascularization by suppressing the endothelial-to-mesenchymal transition via the TGF-β/Smad and MAPKs signaling pathways.American journal of translational research · 2026Article
- ProbioticAntioxidants (Basel, Switzerland) · 2025Article
- Artificial intelligence-driven diagnosis for age-related macular degeneration bridging pathology and engineering: a survey.International ophthalmology · 2025Review
- Retinal Protective Effect of Mono-Ethyl Fumarate in Experimental Age-Related Macular Degeneration via Anti-Oxidative and Anti-Apoptotic Alterations.International journal of molecular sciences · 2025Article
- Age- and sex- divergent translatomic responses of the mouse retinal pigmented epithelium.Neurobiology of aging · 2024Article
- Ranibizumab Modifies the Expression of Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Mononuclear Cells in Patients with Exudative Age-Related Macular Degeneration.Journal of clinical medicine · 2024Article
- Oncostatin M Reduces Pathological Neovascularization in the Retina Through Müller Cell Activation.Investigative ophthalmology & visual science · 2024Article
- Examination of Inner Retinal Layers in Unilateral Wet Age-Related Macular Degeneration Treated with Anti-VEGF, Compared to Fellow Untreated Eyes.International journal of molecular sciences · 2022Article
- Characterization and identification of measurable endpoints in a mouse model featuring age-related retinal pathologies: a platform to test therapies.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- Systemic Complement Activation Profiles in Nonexudative Age-Related Macular Degeneration: A Systematic Review.Ophthalmology science · 2022Article
- AMD Genomics: Non-Coding RNAs as Biomarkers and Therapeutic Targets.Journal of clinical medicine · 2022Review
- Transcription factor Foxp1 is essential for the induction of choroidal neovascularization.Eye and vision (London, England) · 2022Article
- Osteopontin accumulates in basal deposits of human eyes with age-related macular degeneration and may serve as a biomarker of aging.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Generation of an RCVRN-eGFP Reporter hiPSC Line by CRISPR/Cas9 to Monitor Photoreceptor Cell Development and Facilitate the Cell Enrichment for Transplantation.Frontiers in cell and developmental biology · 2022Article
- Novel Epigenetic Clock Biomarkers of Age-Related Macular Degeneration.Frontiers in medicine · 2022Article
- A Systematic Review of Carotenoids in the Management of Age-Related Macular Degeneration.Antioxidants (Basel, Switzerland) · 2021Review
- Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Age Related Macular Degeneration, Role in Pathophysiology, and Possible New Therapeutic Strategies.Antioxidants (Basel, Switzerland) · 2021Review
- A defined subset of clonal retinal stem cell spheres is biased to RPE differentiation.iScience · 2021Article
- Age-related macular degeneration.Nature reviews. Disease primers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
While the development of anti-vascular endothelial growth factor (anti-VEGF) as a therapy for neovascular age-related macular degeneration (AMD) was a great success, the pathologic processes underlying dry AMD that eventually leads to photoreceptor dysfunction, death, and vision loss remain elusive to date, with a lack of effective therapies and increasing prevalence of the disease. There is an overwhelming need to improve the classification system of AMD, to increase our understanding of cell death mechanisms involved in both neovascular and non-neovascular AMD, and to develop better biomarkers and clinical endpoints to eventually be able to identify better therapeutic targets-especially early in the disease process. There is no doubt that it is a matter of time before progress will be made and better therapies will be developed for non-neovascular AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.